Association of dialysis facility-level hemoglobin measurement and erythropoiesis-stimulating agent dose adjustment frequencies with dialysis facility-level hemoglobin variation: A retrospective analysis

BMC Nephrology

Volumn 12, Issue 1, 2011, Pages

  Khan, Irfan ^a   Krishnan, Mahesh ^b   Kothawala, Anupam ^a   Ashfaq, Akhtar ^a  

^a AMGEN INC   (United States)

^b DAVITA INC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

HEMOGLOBIN; RECOMBINANT ERYTHROPOIETIN; ANTIANEMIC AGENT;

ARTICLE; CLINICAL PRACTICE; DIALYSIS; FOLLOW UP; HEALTH CARE FACILITY; HEMOGLOBIN BLOOD LEVEL; HUMAN; MAJOR CLINICAL STUDY; MEASUREMENT; OUTCOME ASSESSMENT; PREDICTIVE VALUE; ANEMIA; BIOLOGICAL MODEL; BLOOD; CHRONIC KIDNEY FAILURE; DOSE RESPONSE; METABOLISM; RENAL REPLACEMENT THERAPY; RETROSPECTIVE STUDY; TREATMENT OUTCOME;

ANEMIA; DOSE-RESPONSE RELATIONSHIP, DRUG; HEMATINICS; HEMOGLOBINS; HUMANS; KIDNEY FAILURE, CHRONIC; MODELS, BIOLOGICAL; PHYSICIAN'S PRACTICE PATTERNS; RENAL DIALYSIS; RETROSPECTIVE STUDIES; TREATMENT OUTCOME;

EID: 79956192562     PISSN: None     EISSN: 14712369     Source Type: Journal    
DOI: 10.1186/1471-2369-12-22     Document Type: Article

References (32)

1. Protocol adherence and the ability to achieve target haemoglobin levels in haemodialysis patients. K Chan J Moran M Hlatky R Lafayette, Nephrol Dial Transplant 2009 24 6 1956 1962 10.1093/ndt/gfn780 19176685
2. Facility factors dominate the ability to achieve target haemoglobin levels in haemodialysis patients. KE Chan RA Lafayette AS Whittemore MA Hlatky J Moran, Nephrol Dial Transplant 2008 23 9 2948 2956 10.1093/ndt/gfn172 18469314
3. Hemoglobin cycling in hemodialysis patients treated with recombinant human erythropoietin. S Fishbane JS Berns, Kidney Int 2005 68 3 1337 1343 10.1111/j.1523-1755.2005.00532.x 16105069 (Pubitemid 43246455)
4. Evidence and implications of haemoglobin cycling in anaemia management. S Fishbane JS Berns, Nephrol Dial Transplant 2007 22 8 2129 2132 10.1093/ndt/gfm384 17595177 (Pubitemid 47244687)
5. Hemoglobin variability in anemia of chronic kidney disease. K Kalantar-Zadeh GR Aronoff, J Am Soc Nephrol 2009 20 3 479 487 10.1681/ASN.2007070728 19211716
6. Computerized decision support for EPO dosing in hemodialysis patients. DC Miskulin DE Weiner H Tighiouart V Ladik K Servilla PG Zager A Martin HK Johnson KB Meyer, Am J Kidney Dis 2009 54 6 1081 1088 10.1053/j.ajkd.2009.07.010 19781831
7. Managing anemia in dialysis patients: hemoglobin cycling and overshoot. AK Singh E Milford S Fishbane SR Keithi-Reddy, Kidney Int 2008 74 5 679 683 10.1038/ki.2008.59 18337717
8. Aranesp(darbepoetin alfa), Full Prescribing Information, Amgen, Inc., Thousand Oaks, CA 2010
9. Epogen(epoetin alfa), Full Prescribing Information, Amgen, Inc., Thousand Oaks, CA 2010
10. KDOQI clinical practice guideline and clinical practice recommendations for anemia in chronic kidney disease: 2007 update of hemoglobin target. Am J Kidney Dis 2007 50 3 471 530 17720528
11. The effects of normal as compared with low hematocrit values in patients with cardiac disease who are receiving hemodialysis and epoetin. A Besarab WK Bolton JK Browne JC Egrie AR Nissenson DM Okamoto SJ Schwab DA Goodkin, N Engl J Med 1998 339 9 584 590 10.1056/NEJM199808273390903 9718377 (Pubitemid 28385655)
12. Normalization of hemoglobin level in patients with chronic kidney disease and anemia. TB Drueke F Locatelli N Clyne KU Eckardt IC Macdougall D Tsakiris HU Burger A Scherhag, N Engl J Med 2006 355 20 2071 2084 10.1056/NEJMoa062276 17108342 (Pubitemid 44749316)
13. A trial of darbepoetin alfa in type 2 diabetes and chronic kidney disease. MA Pfeffer EA Burdmann CY Chen ME Cooper D de Zeeuw KU Eckardt JM Feyzi P Ivanovich R Kewalramani AS Levey EF Lewis JB McGill JJ McMurray P Parfrey HH Parving G Remuzzi AK Singh SD Solomon R Toto, N Engl J Med 2009 361 21 2019 2032 10.1056/NEJMoa0907845 19880844
14. Correction of anemia with epoetin alfa in chronic kidney disease. AK Singh L Szczech KL Tang H Barnhart S Sapp M Wolfson D Reddan, N Engl J Med 2006 355 20 2085 2098 10.1056/NEJMoa065485 17108343 (Pubitemid 44749317)
15. Death, hospitalization, and economic associations among incident hemodialysis patients with hematocrit values of 36 to 39%. AJ Collins S Li W St Peter J Ebben T Roberts JZ Ma W Manning, J Am Soc Nephrol 2001 12 11 2465 2473 11675424 (Pubitemid 33021125)
16. The impact of anemia on cardiomyopathy, morbidity, and mortality in end-stage renal disease. RN Foley PS Parfrey JD Harnett GM Kent DC Murray PE Barre, Am J Kidney Dis 1996 28 1 53 61 10.1016/S0272-6386(96)90130-4 8712222 (Pubitemid 26231466)
17. The relative contribution of measured variables to death risk among hemodialysis patients. EG Lowrie WH Huang NL Lew Y Liu, Death on Hemodialysis: Preventable or Inevitable, Hingman FE. Boston, MA: Kluwer Academic Publishers, 1994 121 141
18. Hematocrit level and associated mortality in hemodialysis patients. JZ Ma J Ebben H Xia AJ Collins, J Am Soc Nephrol 1999 10 3 610 619 10073612 (Pubitemid 29117643)
19. The effects of higher hemoglobin levels on mortality and hospitalization in hemodialysis patients. N Ofsthun J Labrecque E Lacson M Keen JM Lazarus, Kidney Int 2003 63 5 1908 1914 10.1046/j.1523-1755.2003.00937.x 12675871 (Pubitemid 36513341)
20. Associations between changes in hemoglobin and administered erythropoiesis-stimulating agent and survival in hemodialysis patients. DL Regidor JD Kopple CP Kovesdy RD Kilpatrick CJ McAllister J Aronovitz S Greenland K Kalantar-Zadeh, J Am Soc Nephrol 2006 17 4 1181 1191 10.1681/ASN.2005090997 16565261
21. Anaemia and mortality in haemodialysis patients: interaction of propensity score for predicted anaemia and actual haemoglobin levels. TL Roberts RN Foley ED Weinhandl DT Gilbertson AJ Collins, Nephrol Dial Transplant 2006 21 6 1652 1662 10.1093/ndt/gfk095 16449283 (Pubitemid 43834645)
22. Medicare program; end-stage renal disease quality incentive program. Centers for Medicare & Medicaid Services, Final rule, Services DoHaH. Federal Register, 2011 76 628 646
23. Changes in hemoglobin level distribution in US dialysis patients from June 2006 to November 2008. DM Spiegel I Khan M Krishnan TJ Mayne, Am J Kidney Dis 2010 55 1 113 120 10.1053/j.ajkd.2009.09.024 19932539
24. Longitudinal modeling of age-related memory decline and the APOE epsilon4 effect. RJ Caselli AC Dueck D Osborne MN Sabbagh DJ Connor GL Ahern LC Baxter SZ Rapcsak J Shi BK Woodruff DE Locke CH Snyder GE Alexander R Rademakers EM Reiman, N Engl J Med 2009 361 3 255 263 10.1056/NEJMoa0809437 19605830
25. GM Fitzmaurice NM Laird JH Ware, Applied Longitudinal Analysis New York, NY: John Wiley and Sons 2004
26. Longitudinal and cross-sectional estimates of pulmonary function decline in never-smoking adults. JH Ware DW Dockery TA Louis XP Xu BG Ferris FE Speizer, Am J Epidemiol 1990 132 4 685 700 2403109 (Pubitemid 20344536)
27. Effect of variability in anemia management on hemoglobin outcomes in ESRD. E Lacson N Ofsthun JM Lazarus, Am J Kidney Dis 2003 41 1 111 124 10.1053/ajkd.2003.50030 12500228 (Pubitemid 36043358)
28. Parenteral iron use: possible contribution to exceeding target hemoglobin in hemodialysis patients. HN Ibrahim RN Foley R Zhang DT Gilbertson AJ Collins, Clin J Am Soc Nephrol 2009 4 3 623 629 10.2215/CJN.03850808 19211669
29. USRDS 2009 Annual Data Report: Atlas of End-Stage Renal Disease in the United States. US Renal Data System, Bethesda, MD: National Institutes of Health, National Institute of Diabetes and Digestive and Kidney Diseases 2009
30. A practice-related risk score (PRS): a DOPPS-derived aggregate quality index for haemodialysis facilities. DC Mendelssohn RL Pisoni CJ Arrington KE Yeates M Leblanc C Deziel T Akiba M Krishnan S Fukuhara N Lameire FK Port RA Wolfe, Nephrol Dial Transplant 2008 23 10 3227 3233 10.1093/ndt/gfn195 18424461
31. Improvements in dialysis patient mortality are associated with improvements in urea reduction ratio and hematocrit, 1999 to 2002. RA Wolfe TE Hulbert-Shearon VB Ashby S Mahadevan FK Port, Am J Kidney Dis 2005 45 1 127 135 10.1053/j.ajkd.2004.09.023 15696452 (Pubitemid 40038053)
32. Combining ecological and individual variables to reduce confounding by indication: case study - subarachnoid hemorrhage treatment. SC Johnston, J Clin Epidemiol 2000 53 12 1236 1241 10.1016/S0895-4356(00)00251-1 11146270